Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635747 | 0.84 | — | — | |
| SCHEMBL3053970 | 0.80 | GAA (0.42) | HTTALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL2048093 | 0.80 | — | — | |
| SCHEMBL29181 | 0.78 | NPC1 (0.44) | HTTALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL8181923 | 0.78 | NPC1 (0.44) | HTTALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL8204298 | 0.77 | PKM (0.34) | HTTNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL17198007 | 0.77 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL22495389 | 0.76 | HDAC8 (0.65) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL4328483 | 0.75 | ADRB1 (0.47) | ALDH1A1KDM4E | |
| SCHEMBL1035325 | 0.75 | MAPT (0.34) | HTTALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916841-B2 | Inhibitors of phospholipase enzymes | GENETICS INSTITUTE, LLC (US) | 2005-07-12 | — | — | US | claimed |
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-112703231-B | Laminable inks | 阿卡曾塔板材型材有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| CN-108997372-B | Compound for positron imaging, intermediate thereof, preparation method and imaging agent | 华中科技大学同济医学院附属协和医院 | 2020-07-28 | — | — | CN | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-2890691-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | Principia Biopharma Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| CN-103998935-A | Hsp90 combination therapy | SLOAN KETTERING INST CANCER | 2014-08-20 | — | — | CN | disclosed |
| WO-2014036016-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| CN-102970868-A | Treatment of cancers having K-RAS mutations | CURIS INC | 2013-03-13 | — | — | CN | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
| US-4318979-A | COMBINATION TETRAZOLIUM SALT | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1982-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | HTT 3323/4885ALDH1A1 1159/4885NPC1 1740/4885 |
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | HTT 3428/4885ALDH1A1 399/4885NPC1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.